Infusion reactions have been reported with brentuximab vedotin therapy in both clinical trial settings ([@A9]) and in the post clinical trial experience ([@A2]). Infusion reactions can range from minor grade 1 infusion reactions, to anaphylactic reactions, requiring drug discontinuation.

Arora, Bhatt, Liewer, Armitage, and Bociek ([@A1]), reported a case of successful brentuximab vedotin desensitization utilizing a 12-step desensitization protocol for anaphylactic reactions, with increasing dosage and rate over 3 subsequent infusions. Similarly, DeVita, Evens, Rosen, Greenberger, and Petrich ([@A4]) reported a successful 13-step desensitization protocol for the treatment of anaphylaxis related to brentuximab vedotin, which was unresponsive to steroid, antipyretic, antihistamine, and H2 blockade premedications.

As our patient Ms. R had a grade 2 infusion reaction, but no anaphylaxis, we utilized a strategy of steroid, antipyretic, antihistamine, and H2 blockade premedications, without deployment of the full desensitization strategy as described by Arora et al. ([@A1]) and DeVita et al. ([@A4]). This strategy has permitted us to continue full-dose consolidation treatment with brentuximab vedotin without any subsequent infusion reactions. We believe this strategy will provide a useful tool for clinicians in the management of grade 2/3 infusion reactions.
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BACKGROUND
==========

Antibody-drug conjugates (ADCs) are one of the newer types of chemotherapy agents. Brentuximab vedotin is an ADC consisting of a monoclonal antibody targeting CD30, which is overexpressed in Hodgkin lymphoma, and anaplastic large cell lymphoma, conjugated with monomethyl auristatin E (MMAE). This microtubule-disrupting agent (MMAE) causes cell death.

The drug was developed with the help of a technology lesson from the Indian Ocean sea hare, *Dolabella auricularia* ([@A3]). This sea animal harbors toxic substances that protect it from being eaten. From studying these toxic substances, there arose a drug class known as the auristatins. These auristatins are conjugated with monoclonal antibodies to make the ADC brentuximab. The ADC brentuximab attaches to the tumor-associated antigen, where it is internalized into the cell. Brentuximab then releases its cytotoxic agent, which causes cell death by mitotic disruption similar to the vinca alkaloids.

Brentuximab vedotin was first approved by the US Food and Drug Administration (FDA) for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma on August 19, 2011 ([@A7]). It is approved for second-line therapy in Hodgkin lymphoma and anaplastic large cell lymphoma and as consolidation post autologous transplant in Hodgkin lymphoma ([@A5]).

INFUSION REACTIONS
==================

Brentuximab vedotin, like many monoclonal antibodies, can produce infusion reactions. In phase I clinical trials, there were two cases of anaphylaxis reported. In phase II clinical trials, 12% of patients reported infusion-related reactions ([@A8]).

There are two mechanisms thought to produce infusion-related reactions: anaphylaxis and anaphylactoid reactions. Anaphylaxis is a systemic reaction from the interaction between immunoglobulin E (IgE) and mast cells. Anaphylactoid reactions are cytokine-mediated, rather than IgE-mediated. Clinical manifestations tend to be similar in both types of reactions ([@A8]). The reactions most common with brentuximab vedotin are anaphylactoid, including chills, nausea, dyspnea, pruritus, pyrexia, and cough.

Patients in clinical trials for brentuximab vedotin were tested every 3 weeks for antibodies using a sensitive immunoassay. A total of 7% of patients developed positive antibodies, and 30% developed transiently positive antibodies. A higher incidence of infusion reactions were noted in these persistently positive patients. Patients were also noted to develop these reactions during the second dose, possibly allowing these antibodies to develop after the initial exposure to the medication. There are case reports of patients developing problems as far out as cycle 4.

Another interesting observation is that several of these reactions occurred in patients after transplant ([@A4]). In the case study presented here, Ms. R was not tested for brentuximab antibodies, as she responded to conservative premedication strategies.

DESENSITIZATION PROTOCOLS
=========================

There are several desensitization protocols available for patients who develop anaphylaxis to brentuximab vedotin. A standard 12-step protocol has been successfully used in several patients. The standard 12-step protocol may be used in severe reactions, but only a small subset of patients would require this intense method ([@A1]).

Another example of a rapid desensitization protocol involves premedication with prednisone at 50 mg at 24, 12, and 0 hours prior to infusion, followed by premedication with IV diphenhydramine, IV ranitidine, IV methylprednisolone (125 mg) and oral montelukast 30 minutes prior to the infusion ([@A1]). Another possible strategy was outlined earlier using oral diphenhydramine, oral acetaminophen, IV dexamethasone, and IV famotidine 30 minutes prior to the infusion. Using these various strategies, we can safely infuse brentuximab vedotin to patients with few reactions. The choice of regimen can be made based on the severity of reaction, specifically to the patient.
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